The Global Health Body Sounds Concern Over Acute Lack of Weight-Loss Medications

Under 10% of patients that would benefit from GLP-1 drugs such as Wegovy are able to get them, states the global health agency as it publishes its initial advice on the medications.

With in excess of 1,000,000,000 people worldwide currently living with obesity, it is advocating for increased and just access to these injectable treatments.

According to estimates, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.

"The latest guidance affirms that excess weight is a lifelong illness that can be addressed with thorough and ongoing treatment," remarked its chief Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and distribution challenges are major barriers to universal access to the treatments that can aid individuals in losing significant weight, explains the body.

Weight-Loss Drug Scarcity

Even in the current best projected case, the supply of GLP-1 therapies might only reach approximately 100 million people – fewer than 10% of eligible patients, according to the health organization.

The recommendation urges countries and companies to widen availability, by strategies including licensing agreements.

Exclusive production rights on a key compound – the main ingredient of Novo Nordisk's Wegovy – is due to expire in a number of nations in 2026.

How Weight-Loss Jabs Work

GLP-1 drugs imitate a biological compound to reduce digestion speed, curb appetite and increase feelings of fullness so users reduce food intake.

People typically start to lose weight after several weeks of commencing the regular doses.

Research points to users may put most of the weight back on a year later of halting the drug, as their normal hunger resume.

To be above a healthy weight increases your chance for developing diseases, like diabetes, cardiovascular issues, brain attack, and specific cancers.

Obesity concerns people in every country and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.